Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Verastem, Inc.VSTM · Entity 5242 | Chief Financial Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Verastem, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 123,781 |
Ending reported balance
After 2026-10-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Grant · Disposed 8,333 · Balance 126,347 F1: The reported securities were subject to a performance restricted stock units ("RSU") award that was granted on January 21, 2026. 106,893 RSUs vested on September 30, 2026, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria related to certain clinical development goals had been achieved. Row 2 · 2026-10-01 · Sale · Disposed 2,566 · Balance 123,781 F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were subject to a performance restricted stock units ("RSU") award that was granted on January 21, 2026. 106,893 RSUs vested on September 30, 2026, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria related to certain clinical development goals had been achieved.
F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2023 Filed Jan 31, 2023 21:05 UTC | Verastem, Inc. VSTM · Entity 5242 | GrantStock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001104659-23-008589 · tm234891-1_4seq1.xml · derivative · entry 1 Calkins Daniel · CIK 0001951861 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2033-01-27 F1 · derivative.exercise_date: The option vests as to 25% of the shares on the first anniversary of January 27, 2023 (the "Grant Date") and as to an additional 6.25% of the shares at the end of each successive three-month period following the first anniversary of the Grant Date until the fourth anniversary of the Grant Date (with the number of shares vesting on each vesting date rounded down to the nearest whole share, except with respect to the final vesting date on which all remaining unvested shares shall vest), provided that the Reporting Person continues to serve as an employee of or other service provider to the Issuer on each such vesting date. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:06 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 74 | $0.43 | $31.82 |
DisclosureSEC source: 0001104659-23-002260 · tm232492-1_4seq1.xml · nonDerivative · entry 1 Calkins Daniel · CIK 0001951861 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,517 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 21:07 UTC | Verastem, Inc. VSTM · Entity 5242 | SaleCommon Stock | 1,246 | $0.33 | $411.18 |
DisclosureSEC source: 0001104659-22-130942 · tm2233608-1_4seq1.xml · nonDerivative · entry 1 Calkins Daniel · CIK 0001951861 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,591 F1 · shares: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.